Project CBD

MARCH 21, 2023

All but two of the 45 respondents said they’d consider cannabis as a treatment, with 29 seeking help for sleep disturbances, 27 for emotional complaints, 25 for functional disturbances, and nine for pain. Despite all this, there is a potential biological rationale for the treatment of tinnitus with cannabinoids, the authors explain.

Cannabinoids 144

Cannabinoids Clinical Trials Sleep Blood Pressure 144

Cannabis Law Report

AUGUST 22, 2021

Silo Pharma’s notice of allowance paves the way toward clinical trials for its psychedelics delivery platform using homing peptides. The company believes that the same homing peptide approach could improve the safety and efficacy of psychedelic treatments. Silo Pharma Inc. Looking to the Future. Silo Pharma Inc.

Clinical Trials 105

Clinical Trials Research and Development Safety Treatment 105

Puff Puff Post

JANUARY 1, 2020

One particularly promising area of research is in the treatment of cancer. Cancer patients suffer not only from cancer, but the damaging effects of treatment. Cannabis Cancer Treatments as an Alternative to Opioids. Therefore doctors now consider cannabis as the better treatment option. In some cases opiods work better.

Treatment 64

Treatment Clinical Trials Research and Development Cannabinoids 64

Puff Puff Post

JANUARY 1, 2020

One particularly promising area of research is in the treatment of cancer. Cancer patients suffer not only from cancer, but the damaging effects of treatment. Cannabis Cancer Treatments as an Alternative to Opioids. Therefore doctors now consider cannabis as the better treatment option. In some cases opiods work better.

Treatment 40

Treatment Clinical Trials Research and Development Cannabinoids 40

Cannabis Law Report

OCTOBER 15, 2021

(USOTC: PAOG) cited a British Medical Journal case study report published today on the effectiveness of CBD in the treatment of lung cancer and COPD as validation of PAOG’s ongoing research and development of its own respiratory disorder treatment under the name RespRx. 9,199,960). Billion , and it is expected to reach $16.4

Treatment 52

Treatment Research and Development CBD eCommerce 52

Veriheal

AUGUST 31, 2020

It brings us great pleasure to present the 10 winners of Veriheal’s Innovation in Cannabis Scholarship 2020. Veriheal’s Innovation in Cannabis Scholarship 2020 Winners . Essay: “Integrating Research and Medicine: Cannabis Related Treatment for Neurodegenerative Diseases”. Nishtha Tripathi. School: George Washington University.

Research and Development 117

Research and Development Education Agriculture Patients 117

Cannabis Law Report

FEBRUARY 24, 2022

Subsection 56(1) of the CDSA will exempt medical providers from enforcement of the CDSA when providing psilocybin and MDMA treatment to patients suffering serious or terminal health conditions. Physicians still need SAP approval on a patient-by-patient basis and SAP approval is only granted when other available treatments prove ineffective.

Therapy 52

Therapy Access Clinical Trials Treatment 52

Cannabis Law Report

AUGUST 12, 2021

loss per share, during the same period in 2020 (after including non-cash share-based compensation expense of $11.4 Highlights: Phase IIb COMP360 psilocybin therapy trial for treatment-resistant depression (TRD) close to completion; on track to report data by end of 2021. million during the same period in 2020.

Clinical Trials 98

Clinical Trials Therapy Research and Development Data 98

Cannabis Law Report

AUGUST 10, 2021

This acquisition is focused on becoming the first and only company solving the puzzle of chronic pain with MDMA-based medicines utilizing clinical trials for the purposes of novel drug development. The global chronic pain treatment market is predicted to progress at a CAGR of 6.5% from 2020 to 2030 and generate revenue of $151.7

Chronic Pain 105

Chronic Pain Clinical Trials Research and Development Events 105

Canna Law Blog

NOVEMBER 10, 2020

Public Law 115-176 (“Right to Try”) is a federal law enacted in 2018 that creates a uniform system for terminal patients seeking access to investigational treatments. On July 24, 2020, the agency finally published a proposed rule to facilitate Right to Try reporting requirements (I’m not sure this was even necessary).

Therapy 78

Therapy Clinical Trials Decriminalization Patients 78

Cannabis Law Report

JANUARY 10, 2022

In addition, rising strategic initiatives by key players in the form of collaborations, clinical trials, and production are further contributing to increasing awareness and adoption of THCV products. In 2020, based on application, the others segment accounted for the largest revenue share. Opportunity Analysis (2014-2020-2028).

Cannabinoids 52

Cannabinoids Clinical Trials Research and Development Supply Chain 52

CannaMD

JUNE 2, 2021

In a paper presented at the 2020 International Congress of Parkinson’s Disease and Movement Disorders , the authors reported on the results of an anonymous survey completed by more than 1,000 individuals living with Parkinson’s disease.

Patients 105

Patients Clinical Trials Treatment Research and Development 105

Veriheal

JULY 24, 2023

The 2020 study enlisted 24 participants with depression, giving them varying doses of psilocybin. The study’s results blew researchers away showing that psilocybin’s effect on those with depression “…was about four times larger than what clinical trials have shown for traditional antidepressants on the market”.

Therapy 88

Therapy Clinical Trials Treatment Cannabis 88

NewsMunchies

NOVEMBER 12, 2021

In clinical trials, psilocybin (the psychoactive substance in mushrooms) has shown tremendous promise in treating severe depression, post-traumatic stress disorder, and other mental illnesses. Additional clinical trials underway in the U.S. While the science on psychedelics is exploding, there are roadblocks in the way.

Clinical Trials 90

Clinical Trials Therapy Decriminalization DEA 90

Cannabis Law Report

MAY 10, 2022

Anxiety and sleep disorders were some reasons given for prescriptions despite lack of evidence for cannabis treatment, researchers find. The data also shows that prior to 2020, people between 45 and 52 years old had the highest incidence of prescriptions. We are aware of clinical trials in that space, but not strong evidence.”.

Medicine 52

Medicine Clinical Trials Data Sleep 52

Veriheal

JULY 12, 2021

According to data on Healthy Place , treatment for PTSD is typically accommodated for the general public, of who the vast majority have not experienced military combat. At this time, there is little in the way for combat-related PTSD treatment specifically. But veterans utilize general PTSD treatment and still experience recovery.

Treatment 104

Treatment Sleep Clinical Trials Data 104

Cannabis Law Report

MAY 10, 2022

This is despite a limited number of high-quality clinical trials investigating the drug’s efficacy for this condition. Very few studies have also been done examining cannabis for the treatment of sleep disorders. The findings were published today in Frontiers in Pharmacology. Medicinal cannabis as a last resort.

Medicine 52

Medicine Clinical Trials Sleep Data 52

Cannabis Law Report

OCTOBER 13, 2021

The PCT filing also includes support for future research programs respecting various systems which seek to minimize negative side effects in psychedelic psychotherapy patients, methods that enable lower and sub-psychedelic doses without impacting treatment efficacy and increasing the long-term efficacy of psychedelic sessions. About Cybin.

Clinical Trials 52

Clinical Trials Research and Development Treatment Conditions 52

TheAnswerPage

FEBRUARY 3, 2020

Is the US VA Office of research and Development conducting any clinical trials that evaluate the use of CBD for the treatment of PTSD? The trial will compare PE + CBD to PE + placebo in a sample of 136 military Veterans with PTSD at the VA San Diego Medical Center. See Answer. See Answer.

Clinical Trials 52

Clinical Trials Research and Development Therapy Treatment 52

SpeedWeed

JULY 23, 2021

When you’re talking about wanting to do an actual clinical trial, you need a diversity of people that participate and one state just does not have the diversity of people that are required,” Towle said. It means] better research, and then that research will lead to better treatments with fewer side effects,” said Towle.

Clinical Trials 52

Clinical Trials Research and Development DEA Cannabinoids 52

Cannabis Law Report

SEPTEMBER 1, 2021

Going public in November 2020 on the NEO exchange, the firm has been steadily growing its market cap and development pipeline. The company recently became the industry’s first firm to list on the NYSE American exchange and their psilocybin clinical trial for depression is making excellent progress. Field Trip Health Ltd.

Research and Development 102

Research and Development Therapy Clinical Trials Pharmaceutical 102

Cannabis Law Report

JULY 9, 2021

Not only are more and more jurisdictions decriminalizing the use of psychedelics for recreational purposes, but it appears that psychedelic substances are the new horizon for the treatment of severe psychological disorders and other ailments. See Deborah Brauser, FDA Permits Psilocybin to Be Tested for Refractory Depression, MEDSCAPE (Oct.

Law 105

Law Therapy Clinical Trials Research and Development 105

The Cannigma

MARCH 18, 2021

Taken together, the lack of guidance and lack of information about what treatments patients are taking, may underlie “inconsistencies in both use and reported effectiveness,” the researchers stated. The study was compiled by way of an anonymous email survey sent to 7,607 people with Parkinson’s disease in January 2020.

Patients 138

Patients Clinical Trials Treatment Cannabis 138

Cannabis Law Report

DECEMBER 21, 2021

This UK-based company caught our attention in 2021 for its team of renowned psychedelic researchers, including chief research officer Professor David Nutt, chief medical officer Dr. Ben Sessa, and head of ketamine psychotherapy Dr. Celia Morgan, as well as its unique studies into ketamine treatment for addiction and gambling addiction.

Clinical Trials 52

Clinical Trials Therapy Treatment DEA 52

Veriheal

FEBRUARY 11, 2021

The objective of the survey published in December 2020 explored “ the effect that medical cannabis has on prescription opioid medication usage for the treatment of chronic pain at three medical cannabis practice sites ”. The Effect of Medical Cannabis on Prescription Opioids.

Chronic Pain 69

Chronic Pain Patients Clinical Trials Treatment 69

TheAnswerPage

MAY 29, 2021

Is haloperidol more effective than odansetron for the treatment of the nausea and vomiting associated with cannabinoid hyperemesis syndrome? According to the results of a randomized controlled trial involving 33 patients with cannabinoid hyperemesis syndrome, haloperidol (0.05 mg/kg or 0.1 Ruberto, A., Sivilotti, M., Forrester, S.,

Clinical Trials 52

Clinical Trials Cannabinoids Treatment Recreational 52

The Cannigma

MAY 19, 2021

This was notoriously reflected in the 2020 arrest of a Japanese man and woman for speaking positively about using cannabis in social media posts. In 2019, Japan approved clinical trials for Epidiolox — a cannabis derived medicine used to treat severe forms of childhood epilepsy such as Dravet and Lennox-Gastaut syndromes.

Law 137

Law Legalization Clinical Trials CBD 137

Veriheal

JULY 16, 2020

Following months of meetings, the Creating Options for Veterans Expedited Recovery ( COVER ) Commission released its report in January 2020. from doing any research about the efficacy or risks of these treatment options. The supply of research-grade cannabis, together with other controlled substances, is woefully inadequate.

Research and Development 81

Research and Development Clinical Trials Treatment Compliance 81

Cannabis Law Report

OCTOBER 15, 2021

At Kidney Week 2021, Goldfinch Bio will present multiple e-posters, including: The design of TRACTION-2, the ongoing Phase 2 clinical trial evaluating GFB-887 for the treatment of focal segmental glomerulosclerosis (FSGS) and diabetic nephropathy (DN). CAMBRIDGE, Mass.–(BUSINESS

Clinical Trials 52

Clinical Trials Research and Development Data Patients 52

Cannabis Law Report

MAY 29, 2022

Widespread approval for psychedelic treatments remains unlikely, but the tide is slowly turning. In 2020, Oregon became the first locale to decriminalize psilocybin and legalize it for therapeutic use on a statewide basis. In 2019, FDA approved Spravato (esketamine) nasal spray for treatment of depression in adults. [8]

Research and Development 52

Research and Development DEA Clinical Trials Therapy 52

Healer

MARCH 26, 2021

Gresh has joined a growing number of patients who swear by medical cannabis not only as a treatment option for chronic pain, but also as a substitute for prescription opioids used in pain management. It’s estimated that 2020 spending was about $48 million. . The researchers stressed the need for large, well-designed clinical trials.

Chronic Pain 86

Chronic Pain Clinical Trials Treatment Patients 86

Cannabis Law Report

FEBRUARY 28, 2022

Clinical trials are producing promising results, creating enthusiasm for commercializing and patenting psychedelics. 649, 654 (2020). 1025, 1026 (2021) (reporting significant improvement of PTSD symptoms following treatment with MDMA in clinical trial); see also Alec J. 2 × 2. Mitchell et al.,

Research and Development 52

Research and Development Therapy Law Clinical Trials 52

Veriheal

NOVEMBER 17, 2020

According to the Ohio State Medical Marijuana website, the petition will not be considered if received after December 31, 2020, if it seeks to add a broad category of diseases or conditions, or if the condition is one that has been previously reviewed by the board and rejected unless new scientific research that supports the request is offered.

Conditions 98

Conditions Research and Development Pharmaceutical Clinical Trials 98

Cannabis Law Report

JANUARY 13, 2020

12, 2020 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, today reported preliminary, unaudited net product sales for the fourth quarter and full-year 2019 and key priorities for 2020. Key Priorities for 2020.

Pharmaceutical 66

Pharmaceutical Clinical Trials Research and Development Programs 66

Cannabis Law Report

DECEMBER 17, 2021

In 2020, the total prevalent cases of 22q11.2 deletion syndrome cases in the 7MM, accounting for approximately 42% of the total 7MM cases in 2020. deletion syndrome were in Germany and the least in Spain in 2020. deletion syndrome were in Germany and the least in Spain in 2020. deletion syndrome were 35,203 in 2020.

Clinical Trials 52

Clinical Trials Research and Development Pharmaceutical Therapy 52

Cannabis Law Report

AUGUST 25, 2021

“Lucid has successfully developed a strong pipeline of novel therapeutic compounds — supported by IP in order to advance to future clinical trials — and we are confident that the experience the Lucid leadership team brings will allow us to immediately start the process towards clinical trials to further advance these promising therapies.

Clinical Trials 111

Clinical Trials Research and Development Therapy Conditions 111

Cannabis Law Report

FEBRUARY 10, 2022

Despite Petitioners’ noble cause, the case turned on a technicality after the Court determined that the DEA’s letter stating that such psilocybin treatment was not allowed, the document that prompted the lawsuit, was not a “final” decision of the Attorney General that the Court had jurisdiction to review. Background. Psilocybin. The RTT Act.

DEA 52

DEA Clinical Trials Policy Research and Development 52